Abbott Laboratories, Abbott Park, Ill, has introduced Alinity, its state-of-the-art, harmonized family of systems for clinical diagnostics, to the US market. According to the company, more than 1,000 Alinity instruments have already been ordered or installed globally, indicating high demand for the systems’ advanced capabilities and potential to provide savings and increased efficiencies for labs, clinicians, and hospitals.
Brian Blaser, Abbott.
“Abbott’s Alinity portfolio has the potential to take labs to the next level and healthcare to a better place,” says Brian Blaser, executive vice president for diagnostic products at Abbott. “Imagine getting faster test results for you and your loved ones and providing a safe blood supply to the population. Alinity can help do all of this more quickly than ever before.”
The Alinity portfolio includes systems for clinical chemistry, immunoassays, molecular diagnostics, hematology, point-of-care testing, and blood and plasma screening. Key features include smart capabilities that upgrade diagnostic test speed, volume, and efficiency within a smaller and more versatile platform that is flexible and scalable. The systems’ compact design can significantly reduce the instrument footprint in the core lab, by nearly 50% in some cases. Additionally, proprietary lock-and-key reagent bottles ensure that reagents can only fit in designated positions, safeguarding against error.
Combined with AlinIQ, a first-of-its-kind, holistic suite of professional services that combines expertise with process analysis and informatics, Alinity helps labs and hospital systems solve some of their most pressing challenges to deliver better patient care with fewer resources. This is especially important as global testing volumes rise due to an aging population, the growing management of diseases, and increased access to care. At the same time, health systems face pressures to perform testing as efficiently as possible with limited staff and space, while also reducing costs.
To develop the Alinity platform, Abbott’s research and development teams engaged with thousands of clinicians, scientists, lab technicians, and healthcare executives to better understand their experiences and address challenges they face, whether in the core laboratory, at the point of care, or in molecular diagnostics.
Alinity is designed to be intuitive and easy to use, with an integrated, common interface across instruments that makes it quick to learn and easy to use for all lab personnel. It is continuously accessible to run any test at any time, and offers users the ability to replace reagents without stopping the instrument, which improves lab productivity. Flexibility and scalability enable labs to add modules over time as testing volumes increase, without having to replace entire systems.
Managed by properly trained technical personnel, Alinity systems facilitate the automation of many exams and ensure traceability of the sample and prevention of process errors. The introduction of Abbott’s harmonized family of cutting-edge diagnostics systems to the US market begins with the Alinity c clinical chemistry system and Alinity i immunoassay system, which can operate individually or as an integrated Alinity series.
To learn more, visit Abbot.
